3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
352
Neoplasm Metastasis
31
Stomach Neoplasms
30
HER2-positive Breast Cancer
19
Neoplasms
16
Breast Neoplasms, Male
16
Brain Neoplasms
13
Inflammatory Breast Neoplasms
12
Esophageal Neoplasms
10
Colorectal Neoplasms
10
Triple Negative Breast Neoplasms
8
Adenocarcinoma
7
Prostatic Neoplasms
6
Cardiotoxicity
6
Carcinoma, Non-Small-Cell Lung
6
Ovarian Neoplasms
5
Lung Neoplasms
5
Carcinoma, Ductal, Breast
5
Biliary Tract Neoplasms
5
Salivary Gland Neoplasms
4
Pathologic Complete Response
4
Pancreatic Neoplasms
4
Meningeal Neoplasms
4
Colonic Neoplasms
4
Breast Diseases
4
Recurrence
3
Rectal Neoplasms
3
Meningeal Carcinomatosis
3
Gallbladder Neoplasms
3
Carcinoma, Lobular
3
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Dihydropyrimidine Dehydrogenase Deficiency
×
Trastuzumab
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled